Moderna stock surges 60% after landmark melanoma vaccine win
Moderna stock rocketed roughly 60% in pre-market trading on August 19, 2026, after the company and Merck announced their personalised mRNA cancer vaccine met its primary goal in a landmark Phase 3 trial — the first time an mRNA-based cancer therapy has ever succeeded at this stage. The result is being called a watershed moment for oncology and mRNA medicine alike.
Key Takeaways
- Moderna (MRNA) shares surged ~60% pre-market on August 19, 2026, one of the stock's biggest single-day moves ever.
- The Phase 3 INTerpath-001 trial of intismeran autogene (mRNA-4157) combined with Merck's Keytruda met its primary endpoint of recurrence-free survival (RFS) in resected stage IIB-IV melanoma.
- This is the first positive Phase 3 readout for any individualised neoantigen therapy and any mRNA-based cancer treatment.
- The combination beat Keytruda alone — the current standard of care — marking the first Phase 3 study to do so in the adjuvant melanoma setting.
- Merck and Moderna plan to present full data at an upcoming international medical meeting and begin regulatory filing discussions.
What exactly did the melanoma vaccine trial show?
The INTerpath-001 Phase 3 trial evaluated intismeran autogene — a personalised mRNA vaccine tailored to each patient's unique tumour mutations — given alongside Merck's blockbuster immunotherapy Keytruda (pembrolizumab). At a pre-specified interim analysis, the combination delivered statistically significant and clinically meaningful improvements in both recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) versus Keytruda alone in patients with completely resected stage IIB-IV cutaneous melanoma who had received no prior systemic therapy.
Earlier Phase 2b data, including five-year follow-up presented at the 2026 ASCO Annual Meeting, had already shown a 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of distant metastasis or death compared with Keytruda alone. The Phase 3 result now confirms those findings at the highest level of clinical evidence.
Why does this matter beyond moderna stock?
The trial represents two firsts simultaneously: the first Phase 3 win for any individualised neoantigen therapy (INT), and the first Phase 3 win for any mRNA-based cancer treatment. That distinction is significant because it validates the entire platform — not just one drug. Scientists have long theorised that teaching the immune system to recognise a patient's own tumour fingerprint could transform cancer care; this result is the clearest proof yet that the theory works in practice.
Keytruda is already the global standard of care for adjuvant treatment after melanoma surgery, so beating it head-to-head in a rigorous Phase 3 study is a high bar. The combination's success suggests regulators could have a compelling data package to review in the coming months. Merck shares also climbed around 6% in pre-market trading on the news, reflecting the partnership's shared upside.
What happens next for the vaccine and for investors?
Merck and Moderna said they will present the full INTerpath-001 dataset at an upcoming international medical conference and will engage with regulators on filing submissions for intismeran autogene in combination with Keytruda. The trial will also continue to evaluate overall survival (OS) as a key secondary endpoint — a figure that will be central to any eventual approval label and pricing discussions.
For investors tracking breaking science and health stories, the moderna stock move is a reminder of how quickly mRNA biotechs can re-rate on clinical data. The next catalyst will be the conference presentation and the first regulatory submission date. For patients, the stakes are even higher: melanoma remains one of the deadliest skin cancers, and an approved personalised vaccine could change the treatment landscape entirely. Full trial details are available via RTT News.